预防骨质疏松性骨折的筛查:美国预防服务工作组更新证据报告与系统综述
该更新系统综述为美国预防服务工作组汇总了筛查与治疗预防骨质疏松性骨折的证据。HR 0.72,95%CI 0.59-0.89);女性中双膦酸盐等药物降低椎体骨折风险,双膦酸盐和地舒单抗降低非椎体骨折风险,地舒单抗降低髋部骨折风险,治疗危害证据不一致。
要点
- 筛查可能减少女性髋部骨折,一项RCT显示髋部骨折2.6% vs 3.5%(HR 0.72,95%CI 0.59-0.89)。
- 女性双膦酸盐、甲状旁腺激素、雷洛昔芬和地舒单抗降低椎体骨折风险(9项试验,RR 0.32-0.64)。
- 骨测量测试和临床风险评估识别骨质疏松或预测骨折的准确性从很差到良好不等。
核心结论
- 在女性中,预防骨质疏松性骨折的筛查可能减少髋部骨折,治疗降低椎体和非椎体骨折风险,治疗危害证据不一致。
- 骨测量测试或临床风险评估识别骨质疏松或预测骨折的准确性从很差到良好不等。
研究设计与样本
- 研究对象为40岁及以上成人,筛查队列无 prevalent 低创伤骨折或治疗队列骨折风险增加,评估筛查、骨测量测试或临床风险评估、药物治疗。
- 采用双人独立审查、研究质量评级和随机效应荟萃分析。
主要发现
- 骨测量测试识别骨质疏松的准确性AUC范围为0.32-0.89。
- 临床风险评估识别骨质疏松的合并准确性在女性中AUC为0.65-0.76,男性中为0.76-0.80;预测骨折的准确性相似。
关键数值与推荐
- 筛查与不筛查比较:髋部骨折2.6% vs 3.5%;HR 0.72(95%CI 0.59-0.89)。
- 髋部骨折:地舒单抗RR 0.60(95%CI 0.37-0.97;1项RCT,n=7868);双膦酸盐合并RR 0.70(95%CI 0.44-1.11;3项RCT,n=8988)。
- 男性放射学椎体骨折:唑来膦酸RR 0.33(95%CI 0.16-0.70;1项RCT,n=1199)。
临床怎么用
- 临床可参考本证据评估女性骨质疏松筛查与治疗对骨折风险的影响。
- 女性药物治疗选择需权衡椎体、非椎体及髋部骨折风险降低证据及潜在危害。
- 骨测量测试和临床风险评估的准确性差异较大,解读结果时应结合个体情况。
局限性
- 男性治疗证据有限,主要来自唑来膦酸单研究,缺乏临床或髋部骨折减少证据。
- 双膦酸盐与髋部骨折关联未达统计学显著。
- 治疗危害证据不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Osteoporotic fractures cause significant morbidity and mortality. OBJECTIVE: To update the evidence on screening and treatment to prevent osteoporotic fractures for the US Preventive Services Task Force. DATA SOURCES: PubMed, the Cochrane Library, EMBASE, and trial registries (November 1, 2009, through October 1, 2016) and surveillance of the literature (through March 23, 2018); bibliographies from articles. STUDY SELECTION: Adults 40 years and older; screening cohorts without prevalent low-trauma fractures or treatment cohorts with increased fracture risk; studies assessing screening, bone measurement tests or clinical risk assessments, pharmacologic treatment. DATA EXTRACTION AND SYNTHESIS: Dual, independent review of titles/abstracts and full-text articles; study quality rating; random-effects meta-analysis. MAIN OUTCOMES AND MEASURES: Incident fractures and related morbidity and mortality, diagnostic and predictive accuracy, harms of screening or treatment. RESULTS: One hundred sixty-eight fair- or good-quality articles were included. One randomized clinical trial (RCT) (n = 12 483) comparing screening with no screening reported fewer hip fractures (2.6% vs 3.5%; hazard ratio [HR], 0.72 [95% CI, 0.59-0.89]) but no other statistically significant benefits or harms. The accuracy of bone measurement tests to identify osteoporosis varied (area under the curve [AUC], 0.32-0.89). The pooled accuracy of clinical risk assessments for identifying osteoporosis ranged from AUC of 0.65 to 0.76 in women and from 0.76 to 0.80 in men; the accuracy for predicting fractures was similar. For women, bisphosphonates, parathyroid hormone, raloxifene, and denosumab were associated with a lower risk of vertebral fractures (9 trials [n = 23 690]; relative risks [RRs] from 0.32-0.64). Bisphosphonates (8 RCTs [n = 16 438]; pooled RR, 0.84 [95% CI, 0.76-0.92]) and denosumab (1 RCT [n = 7868]; RR, 0.80 [95% CI, 0.67-0.95]) were associated with a lower risk of nonvertebral fractures. Denosumab reduced the risk of hip fracture (1 RCT [n = 7868]; RR, 0.60 [95% CI, 0.37-0.97]), but bisphosphonates did not have a statistically significant association (3 RCTs [n = 8988]; pooled RR, 0.70 [95% CI, 0.44-1.11]). Evidence was limited for men: zoledronic acid reduced the risk of radiographic vertebral fractures (1 RCT [n = 1199]; RR, 0.33 [95% CI, 0.16-0.70]); no studies demonstrated reductions in clinical or hip fractures. Bisphosphonates were not consistently associated with reported harms other than deep vein thrombosis (raloxifene vs placebo; 3 RCTs [n = 5839]; RR, 2.14 [95% CI, 0.99-4.66]). CONCLUSIONS AND RELEVANCE: In women, screening to prevent osteoporotic fractures may reduce hip fractures, and treatment reduced the risk of vertebral and nonvertebral fractures; there was not consistent evidence of treatment harms. The accuracy of bone measurement tests or clinical risk assessments for identifying osteoporosis or predicting fractures varied from very poor to good.
引用
- Viswanathan M, Reddy S, Berkman N, et al. Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018. PMID: 29946734. doi:10.1001/jama.2018.6537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。